bpc 157 hims The peptide craze Hims & Hers stock rises
Hims & Hers stock rises as FDA schedules peptide review BPC 157 Mark Hyman, MD HIMS jumps more than 7% after an FDA panel recommends adding BPC 157 to the 503A compounding list potentially opening a new peptide category. The opportunity fits Hims existing telehealth, compounding and customer Wolverine Stack Peptide Therapy (BPC 157 + TB 500) $330 OFH
Pay in 4 interest-free payments of $6.08 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Jul 30 - Aug 4



